Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Gene Biotech Co., Ltd. (086060:KRX), powered by AI.
Gene Biotech Co., Ltd. is currently trading at ₩3,895. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Gene Biotech Co., Ltd. on Alpha Lenz.
Gene Biotech Co., Ltd.'s P/E ratio is 8.9.
“Gene Biotech Co., Ltd. trades at a P/E of 8.9 (undervalued) with modest ROE of 7.2%.”
Ask for details →Gene Biotech Co., Ltd. is a biotechnology company specializing in the research, development, and commercialization of bio-based products. Its primary function is to harness genetic engineering and biotechnology to create applications in the health and pharmaceutical industries. Notable features of Gene Biotech include its focus on developing innovative solutions for genetic therapies, DNA analysis tools, and bioengineering products that can advance healthcare treatments and diagnostic capabilities. The company plays a significant role in the pharmaceutical sector by offering cutting-edge technologies that address unmet medical needs and improve patient outcomes. Its contributions to the biotech sphere are critical, as it helps facilitate the next generation of medical solutions, thereby impacting public health and safety globally. Gene Biotech Co., Ltd.'s research initiatives and product pipelines position it as a key player in the biotechnology market, with a strong emphasis on sustainable and effective therapeutic development.
“Gene Biotech Co., Ltd. trades at a P/E of 8.9 (undervalued) with modest ROE of 7.2%.”
Ask for details →Gene Biotech Co., Ltd. (ticker: 086060) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $33.5B.
The current price is ₩3,895 with a P/E ratio of 8.85x and P/B of 0.61x.
ROE is 7.15% and operating margin is 4.40%. Annual revenue is $90.8B.